Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report report published on Saturday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Price Performance

Accelerate Diagnostics stock opened at $1.04 on Friday. The firm’s fifty day moving average price is $1.18 and its 200 day moving average price is $1.52. The company has a market capitalization of $26.05 million, a price-to-earnings ratio of -0.36 and a beta of 0.61. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in Accelerate Diagnostics during the 4th quarter worth $27,000. Y Intercept Hong Kong Ltd bought a new position in shares of Accelerate Diagnostics during the third quarter worth about $34,000. Renaissance Technologies LLC grew its stake in Accelerate Diagnostics by 160.6% in the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after purchasing an additional 65,984 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Accelerate Diagnostics by 6.9% in the fourth quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock valued at $163,000 after buying an additional 8,777 shares during the last quarter. 17.14% of the stock is currently owned by institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.